OLMA beat EPS expectations by 21.88%
Mar 26, 2025, 10:32 PM
0.00%
What does OLMA do
Olema Pharmaceuticals, based in San Francisco, develops targeted therapies for women's cancers, notably its lead candidate OP-1250, currently in Phase I/II trials for metastatic ER-positive breast cancer. The company went public on November 19, 2020, and employs 75 staff.
Olema Pharmaceuticals (OLMA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Olema Pharmaceuticals's actual EPS was -$0.51, beating the estimate of -$0.65 per share, resulting in a 21.88% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.